Novo Nordisk AS
NVO
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2024
Employees
72,000
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,415.00 | 100.20 | -1.18% |
CAC 40 | 7,226.98 | 199.90 | -2.69% |
DAX 40 | 19,033.64 | 414.96 | -2.13% |
Dow JONES (US) | 43,910.98 | 382.15 | -0.86% |
FTSE 100 | 8,025.77 | 99.42 | -1.22% |
HKSE | 19,846.88 | 580.05 | -2.84% |
NASDAQ | 19,281.40 | 17.36 | -0.09% |
Nikkei 225 | 39,287.79 | 88.30 | -0.22% |
NZX 50 Index | 12,641.80 | 107.56 | -0.84% |
S&P 500 | 5,983.99 | 17.36 | -0.29% |
S&P/ASX 200 | 8,152.40 | 103.20 | -1.25% |
SSE Composite Index | 3,421.97 | 48.10 | -1.39% |